| Identification | Back Directory | [Name]
2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole | [CAS]
1401728-56-0 | [Synonyms]
GPR4 antagonist 3
GPR4 antagonist 3(NE 52-QQ57 )
2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole
Pyrazolo[1,5-a]pyrimidine, 2-ethyl-5,7-dimethyl-3-[[4-[5-(4-piperidinyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]- | [Molecular Formula]
C24H28N6O | [MDL Number]
MFCD31813600 | [MOL File]
1401728-56-0.mol | [Molecular Weight]
416.52 |
| Chemical Properties | Back Directory | [density ]
1.32±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:10.0(Max Conc. mg/mL);24.1(Max Conc. mM)
Ethanol:45.0(Max Conc. mg/mL);108.0(Max Conc. mM) | [form ]
Solid | [pka]
9.56±0.10(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Uses]
NE 52-QQ57 is a selective, and orally available GPR4 antagonist with an IC50 of 70 nM. NE 52-QQ57 has anti-inflammatory activity[1]. | [in vivo]
NE 52-QQ57 (Compound 13) shows a significant anti-inflammatory effect in the rat antigen induced arthritis model after oral administration at 30 mg/kg bid for 20 days[1].
NE 52-QQ57 (30 mg/kg bid po for 4 days) also prevents angiogenesis in the mouse chamber model as well as pain as demonstrated in the rat complete Freund’s adjuvant model[1]. | Animal Model: | Female FVB mice (8-10 weeks)[1] | | Dosage: | 30 mg/kg | | Administration: | Oral, 4 days, bid | | Result: | Treatment at 30 mg/kg p.o. bid starting on day 0, the day of the chamber implantation, showed a statistically significant reduction (46.8±10.6%) of tissue growth by day 4. The blood levels of 13 on day 4 at 2 and 16 h after compound application in this model were 9.03±2.87 and 0.09±0.06 μM[1]. |
| Animal Model: | Male Wistar Han rats[1] | | Dosage: | 3, 10, and 30 mg/kg | | Administration: | Oral, 20 days, bid | | Result: | Displayed not only higher exposures in the rat AIA but also lower plasma protein binding in rat (95%)[1]. |
| [References]
[1] Velcicky J, et al. Development of Selective, Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and Angiogenesis. J Med Chem. 2017 May 11;60(9):3672-3683. DOI:10.1021/acs.jmedchem.6b01703
[2] Hosford PS, et al. CNS distribution, signalling properties and central effects of G-protein coupled receptor 4. Neuropharmacology. 2018 Aug;138:381-392. DOI:10.1016/j.neuropharm.2018.06.007 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|